menu
    • menu

    Company profile for Xenetic Biosciences

    NEW Drugs in Dev: 4
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Xenetic Biosciences, Inc. (NASDAQ: XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fu...
    Xenetic Biosciences, Inc. (NASDAQ: XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Xenetic BiosciencesUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    40 Speen Street Suite 102 Framingham, MA 01701
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.xeneticbio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/xenetic-biosciences-inc-
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Natural Products Expo

    Natural Products Expo

    Not Confirmed

    envelop Contact Supplier

    Natural Products Expo

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Xenetic Biosciences Adjourns 2025 Annual Meeting
    Xenetic Biosciences Adjourns 2025 Annual Meeting

    11 Dec 2025

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/biotechnology/xenetic-biosciences-inc.-announces-adjournment-of-2025-annual-meeting-1116916

    ACCESSWIRE
    11 Dec 2025
    Share Share
    Xenetic Biosciences Extends Collaboration With Scripps Research
    Xenetic Biosciences Extends Collaboration With Scripps Research

    19 Nov 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-11-19/xenetic-biosciences-inc-extends-research-and-development-collaboration-with-institute-investigator

    PHARMIWEB
    19 Nov 2025
    Share Share
    Xenetic Biosciences Reports Q3 2025 Financial Results
    Xenetic Biosciences Reports Q3 2025 Financial Results

    13 Nov 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-11-13/xenetic-biosciences-inc-reports-third-quarter-2025-financial-results

    PHARMIWEB
    13 Nov 2025
    Share Share
    Xenetic Biosciences Prices $4.5M Common Stock Offering
    Xenetic Biosciences Prices $4.5M Common Stock Offering

    10 Oct 2025

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/biotechnology/xenetic-biosciences-inc.-announces-pricing-of-4.5-million-underwritten-offering-of-co-1085416

    ACCESSWIRE
    10 Oct 2025
    Share Share
    Xenetic Biosciences Announces Q2 2025 Financial Results
    Xenetic Biosciences Announces Q2 2025 Financial Results

    13 Aug 2025

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/biotechnology/xenetic-biosciences-inc.-reports-second-quarter-2025-financial-results-1060071

    ACCESSWIRE
    13 Aug 2025
    Share Share
    First Patient Dosed in Xenetic’s Pancreatic Cancer Study
    First Patient Dosed in Xenetic’s Pancreatic Cancer Study

    08 Jul 2025

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/biotechnology/xenetic-biosciences-inc.-announces-update-from-collaboration-partner-of-first-patient-1046466

    ACCESSWIRE
    08 Jul 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search